All Stories

  1. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
  2. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography
  3. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
  4. Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' reply
  5. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis
  6. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing
  7. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
  8. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
  9. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
  10. Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis
  11. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study
  12. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort
  13. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference
  14. Impact of steatosis and inflammation definitions on the performance of NASH tests
  15. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective
  16. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
  17. Cystic Fibrosis–related Liver Disease
  18. Impact of graft preservation solutions for liver transplantation on early cytokine release and postoperative organ dysfunctions. A pilot study
  19. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis
  20. Chronic hepatitis E in HIV/HBV coinfected patient
  21. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis
  22. Screening studies of transient elastography and FibroTest in the general population
  23. NAFLD and liver transplantation: Current burden and expected challenges
  24. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
  25. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
  26. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease
  27. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients
  28. Fatty liver is an independent predictor of early carotid atherosclerosis
  29. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion
  30. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury
  31. Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection
  32. Critical comparison of elastography methods to assess chronic liver disease
  33. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
  34. Rate of employment after liver transplantation in France
  35. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
  36. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
  37. Hepatitis E infection in patients with severe alcoholic hepatitis
  38. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study
  39. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
  40. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
  41. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
  42. Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study
  43. Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants
  44. Spontaneous ascitic fluid infection and bacteremia due to Yersinia pseudotuberculosis in a liver transplant patient
  45. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards
  46. Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding
  47. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases
  48. Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms
  49. Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests
  50. Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification
  51. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease
  52. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)
  53. Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival
  54. Impact of common risk factors of fibrosis progression in chronic hepatitis C
  55. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
  56. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: “APRI c’est fini ?”
  57. Spleen Stiffness Measurement by Transient Elastography to Diagnose Portal Hypertension in Children
  58. Biopsy as well as FibroTest/Fibrosure Is Suboptimal for Discriminating Intermediate Fibrosis Stages in Patients With Chronic Hepatitis B
  59. Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
  60. FibroTest (FT) has similar accuracy for cirrhosis in ‘intention-to-diagnose’ which is superior to transient elastography (TE) in chronic hepatitis B.
  61. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
  62. The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
  63. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
  64. Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection
  65. Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235]
  66. Correction
  67. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up
  68. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
  69. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
  70. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
  71. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis
  72. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
  73. The use of transient elastography and non-invasive serum markers of fibrosis in pediatric liver transplant recipients
  74. Chronic hepatitis C virus (HCV) disease burden and cost in the United States
  75. Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard
  76. Liver Stiffness, Platelets, and Spleen Size Is Reliable in Nondecompensated Cirrhotic Patients
  77. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin
  78. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study
  79. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease
  80. Optimal nonsurgical management of peptic ulcer bleeding, including arterial embolization is associated with a mortality below 1%
  81. Interferon‐gamma with peginterferon alpha‐2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)
  82. Reply
  83. Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection
  84. Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C
  85. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
  86. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
  87. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection
  88. Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study
  89. Cost-effectiveness modeling of colorectal cancer: Computed tomography colonography vs colonoscopy or fecal occult blood tests
  90. Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis
  91. Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis?
  92. Gastric mucormycosis: A rare cause of gastrointestinal bleeding in cirrhosis
  93. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers
  94. Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
  95. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard
  96. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab
  97. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis
  98. Touching some firm ground in the epidemiology of NASH
  99. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis
  100. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
  101. FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
  102. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis
  103. The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test
  104. Recombinant activated factor VII in chronic liver diseases: Should we be afraid of thromboembolic events?
  105. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)
  106. FibroStic: A large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted
  107. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
  108. Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C
  109. Ranking Hepatologists: Which Hirsch's h-Index to prevent the “e-crise de foi-e”?
  110. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
  111. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  112. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy
  113. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
  114. Perioperative management of combined heart-liver transplantation in patients with cirrhosis, renal insufficiency, or pulmonary hypertension
  115. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program
  116. Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis
  117. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease
  118. High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France
  119. Early Use of TIPS for Cirrhosis and Variceal Bleeding
  120. Hirsch Index and Truth Survival in Clinical Research
  121. A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C
  122. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure
  123. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
  124. Interferon   receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
  125. Assessment of adrenal function in cirrhotic patients: Salivary cortisol should be preferred
  126. Toxicité hépatique de la chimiothérapie du cancer colorectal métastatique: revue de la littérature
  127. Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis
  128. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
  129. Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso
  130. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
  131. Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation
  132. Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers
  133. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
  134. Evaluation of FibroTest–ActiTest in children with chronic hepatitis C virus infection
  135. Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre
  136. Perspectives on fibrosis progression in hepatitis C: an á la carte approach to risk factors and staging of fibrosis
  137. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C
  138. Similarities and Differences Between REPEAT and EPIC3
  139. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials
  140. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
  141. Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV
  142. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?
  143. Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography
  144. Stéatohépatite métabolique : 30 ans de recherches qui ont changé la NASH
  145. Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B
  146. Liver biopsy: The best standard…when everything else fails
  147. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
  148. The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050–60: “Evaluation and improvement of a reliable diagnosis of cirrhosis by ...
  149. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure
  150. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus
  151. Immediate Listing for Liver Transplantation Versus Standard Care for Child–Pugh Stage B Alcoholic Cirrhosis
  152. Discordance between results of biomarkers of fibrosis shows that it is at least a “ménage à deux”
  153. Applicability and variability of liver stiffness measurements according to probe position
  154. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
  155. Perisinusoidal cells (Ito-cells) enlargement in a family with myotonic dystrophy
  156. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions
  157. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
  158. Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
  159. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency
  160. FibroTest-ActiTest as a non-invasive marker of liver fibrosis
  161. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update
  162. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
  163. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease
  164. An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
  165. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
  166. Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes
  167. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma
  168. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence
  169. Adhésion à la bithérapie pégylée au cours de l’hépatite chronique C
  170. Évaluation non-invasive de la fibrose hépatique au cours de l’hépatite C
  171. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers
  172. Assessment of liver fibrosis: Noninvasive means
  173. Chapter 4 Biomarkers Of Liver Fibrosis
  174. Nodular regenerative hyperplasia: The main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities
  175. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C
  176. Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir
  177. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats
  178. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
  179. Meta-analyses of FibroTest diagnostic value in chronic liver disease
  180. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C
  181. FibroMAX™: towards a new universal biomarker of liver disease?
  182. Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages
  183. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C
  184. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability
  185. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
  186. Relationship between the Fibrotest and portal hypertension in patients with liver disease
  187. Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial
  188. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC)
  189. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
  190. Relapse rate of patients after healing of oesophagitis-a prospective study of alginate as self-care treatment for 6 months
  191. Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study
  192. Peut-on traiter la stéatohépatite métabolique ?
  193. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
  194. Faut-il encore faire des biopsies du foie ?
  195. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
  196. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
  197. Association between Leptin, Metabolic Factors and Liver Histology in Patients with Chronic Hepatitis C
  198. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
  199. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
  200. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia
  201. A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C
  202. Erratum
  203. Fibrosis as an End Point for Clinical Trials in Liver Disease: A Report of the International Fibrosis Group
  204. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
  205. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis
  206. Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection
  207. Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?
  208. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease
  209. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
  210. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine
  211. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study
  212. Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant Variants
  213. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers
  214. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level
  215. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
  216. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL)
  217. A novel dendritic cell subset involved in tumor immunosurveillance
  218. Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores
  219. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious
  220. Blood oxidative stress markers are unreliable markers of hepatic steatosis
  221. Diagnostic value of FibroTest with normal serum aminotransferases
  222. Natural history and predictors of disease severity in chronic hepatitis C
  223. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
  224. Lamivudine and HBV-associated nephropathy
  225. A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients
  226. FAS promoter polymorphisms correlate with activity grade in hepatitis C patients
  227. Longitudinal Assessment of Histology Surrogate Markers (FibroTest-ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection
  228. A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B
  229. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
  230. Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy?
  231. Caution before embracing serum markers of liver fibrosis in clinical practice
  232. Management of chronic hepatitis C in French departments of internal medicine and infectious diseases
  233. Age and gender will survive to competing risks as fibrosis factors
  234. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease
  235. Reply:
  236. A reference material for traceability of aspartate aminotransferase (AST) results
  237. FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis?
  238. NASH: a hidden and silent fibroser finally revealed?
  239. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure
  240. Long-term outcome improvement in patients with chronic hepatitis D treated with interferon α
  241. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
  242. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection
  243. The rising health and economic burden of chronic hepatitis C
  244. Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C
  245. Treatment of Hepatitis C Virus: The First Decade
  246. The elusiveness of “normal” ALT in fatty liver
  247. Comparing the public health burden of chronic hepatitis C and HIV infection in France
  248. The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV
  249. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
  250. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
  251. Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
  252. Fat, diabetes, and liver injury in chronic hepatitis C
  253. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
  254. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure
  255. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
  256. The burden cost of French patients suffering from irritable bowel syndrome
  257. Treatment of cirrhotic patients in the pegylated interferon era
  258. Fibrogenic impact of high serum glucose in chro nic hepatitis C
  259. Viral hepatitis B
  260. Viral hepatitis C
  261. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules
  262. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C
  263. Worsening of steatosis and fibrosis progression
  264. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
  265. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
  266. Reversal of cirrhosis: evidence-based medicine?
  267. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
  268. Sarcoidosis and interferon therapy: report of five cases and review of the literature
  269. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence
  270. Noninvasive prediction of fibrosis in patients with chronic hepatitis C
  271. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial
  272. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
  273. Acupuncture for gastrointestinal disorders
  274. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
  275. A comparison of fibrosis progression in chronic liver diseases
  276. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
  277. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C
  278. PEG-interferon versus conventional interferon and liver fibrosis: Do we have evidence of superiority?
  279. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection
  280. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C
  281. Truth Survival
  282. Truth Survival
  283. Portal lymphocytic infiltrate in alcoholic liver disease
  284. Les interférons ont-ils une action antifibrosante ?Le point de vue de l'hépatologue
  285. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection
  286. Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  287. Corrigendum to “Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C” [J Hepatol 36 (2002) 812–818]
  288. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study
  289. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
  290. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients
  291. NNRTI-related or -unrelated hepatotoxicity?
  292. Fatigue in patients with chronic hepatitis C
  293. Truth Survival in Clinical Research: An Evidence-Based Requiem?
  294. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C
  295. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis
  296. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
  297. Individual and evidence-based
  298. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study
  299. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel
  300. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH
  301. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns
  302. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis
  303. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial
  304. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
  305. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis
  306. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model
  307. Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*
  308. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study
  309. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient
  310. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
  311. Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy
  312. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
  313. The role of interleukin-10 in severe acute alcoholic hepatitis
  314. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
  315. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
  316. Une hépatite à cytomégalovirus n’est jamais chronique, et peut en cacher une autre !
  317. Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis
  318. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update
  319. Chronic hepatitis B treatment with lamivudine in kidney transplant patients
  320. Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C
  321. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report
  322. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C
  323. Estimating future hepatitis C morbidity, mortality, and costs in the United States
  324. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis c
  325. Liver fibrosis in overweight patients
  326. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids
  327. Natural history of HCV infection
  328. Appropriateness of Liver Biopsy
  329. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
  330. Is an ?� la carte? combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
  331. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections
  332. EFFECT OF INTERFERON THERAPY ON THE NATURAL HISTORY OF HEPATITIS C VIRUS-RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
  333. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
  334. Extrahepatic manifestations of chronic hepatitis C
  335. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
  336. Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences
  337. A short induction regimen of interferon-α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial
  338. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe
  339. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis
  340. Response to interferon alpha  treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus
  341. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge
  342. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis
  343. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival
  344. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring
  345. Summary of the first international symposium on viral hepatitis
  346. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
  347. Impact of hepatitis B and C virus on kidney transplantation outcome
  348. Diurnal variation of serum alanine transaminase activity in chronic liver disease
  349. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  350. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  351. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis
  352. No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia
  353. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease
  354. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C
  355. Hepatitis C: Somber views of natural history and optimistic views of interferon treatment?
  356. Management of hepatitis C
  357. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro- oesophageal reflux
  358. Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis?
  359. Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis
  360. Thierry Poynard
  361. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
  362. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin
  363. In situ detection of lipid peroxidation by-products in chronic liver diseases
  364. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitisC virus
  365. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features.
  366. Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology
  367. Natural history of liver fibrosis progression in patients with chronic hepatitis C
  368. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis
  369. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis
  370. Histological features predictive of liver fibrosis in chronic hepatitis C infection.
  371. Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases
  372. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
  373. An algorithm for the grading of activity in chronic hepatitis C
  374. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial
  375. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
  376. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix
  377. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix
  378. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease
  379. Heptitis B and C virus infection in HBsAg-negative alcoholics without i.v. drug abuse or previous blood transfusions
  380. A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis
  381. Transforming growth factor?beta 1 (TGF-?1) and TGF-?1 receptors in normal, cirrhotic, and neoplastic human livers*1
  382. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients
  383. Prevalence of Cholelithiasis According to Alcoholic Liver Disease: A Possible Role of Apolipoproteins AI and AII
  384. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine
  385. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy
  386. Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis
  387. Alpha-2-macroglobulin and hepatic fibrosis
  388. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls
  389. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis
  390. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis
  391. A Two-centre, Randomized, Double-blind Trial of Ornithine Oxoglutarate in 194 Elderly, Ambulatory, Convalescent Subjects
  392. No effect of neutralizing antibody to TGF-β1 in acute CC14-induced liver fibrogenesis
  393. Diaphragm Function Is Not Impaired by Pneumoperitoneum After Laparoscopy
  394. Laparoscopic treatment without cholecystectomy for gallbladder perforation after liver biopsy
  395. Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.
  396. Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial
  397. Prednisolone in Severe Alcoholic Hepatitis
  398. Cirrhosis as an independent risk factor for colonic adenomas.
  399. A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis
  400. Anti—pre-S responses and viral clearance in chronic hepatitis B virus infection
  401. Autoimmune Chronic Hepatitis Exacerbated by Alpha-Interferon
  402. Computer-Aided Decision Support in Hepatology
  403. Portal hypertensive colopathy
  404. Reply
  405. Prevention of Gastrointestinal Bleeding in Cirrhosis
  406. Trauma in Cirrhosis: An Indicator of the Pattern of Alcohol Abuse in Different Societies
  407. Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices
  408. Devenir des patients après guérison d’une œsophagite Etude prospective de 1 030 patients pendant 6 mois
  409. Independent risk factors for hepatocellular carcinoma in french drinkers
  410. A biphasic pattern of anti-pre-s responses in acute hepatitis B virus infection
  411. Serum Apolipoprotein A-I in Alcoholic Patients with Chronic Calcifying Pancreatitis
  412. β-blockers and variceal haemorrhage
  413. Long-term results of treatment of vascular malformations of the gastrointestinal tract by neodymium YAG laser photocoagulation
  414. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis
  415. Apolipoproteinemia A and α-fetoprotein in the diagnosis of hepatocellular carcinoma and cirrhosis: Several interpretations
  416. Diagnostic Value of Serum gamma-Glutamyl-Transferase Activity and Mean Corpuscular Volume in Alcoholic Patients with or without Cirrhosis
  417. Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer
  418. Expression of histocompatibility antigens and characterization of the lymphocyte infiltrate in hyperplastic polyps of the large bowel
  419. Statistics in clinical trials
  420. Randomized Double-Blind Clinical Trial of Aluminum Phosphate versus Ranitidine in the Acute Treatment of Duodenal Ulcer
  421. Serial passage of West-European sporadic non-A non-B hepatitis in rhesus monkeys by inoculation with fecal extracts
  422. Apolipoprotein A1 is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients
  423. Endoscopic Nd-YAG laser therapy for palliative treatment of colorectal adenocarcinoma: A multivariate prognostic analysis
  424. Endoscopic laser therapy for duodenal villous adenoma
  425. A randomized study of a coaxial fiber versus a naked fiber for endoscopic Nd:YAG laser therapy of esophageal and rectal tumors
  426. Successful ablation of a large fibrovascular polyp of the esophagus by endoscopic Nd:YAG laser therapy
  427. RECTAL AND COLONIC VARICES IN CIRRHOSIS
  428. A Randomised Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis
  429. Prognostic evaluation in cirrhosis
  430. Detection of hepatitis B surface antigen by a monoclonal radioimmunoassay in the serum of alcoholic patients
  431. Response to hewitt et al: Retrieval of randomized clinical trials in liver disease
  432. A DECADE OF CAMPYLOBACTER PYLORI
  433. Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients
  434. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis
  435. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding
  436. Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis
  437. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol
  438. Gastric phytobezoar destruction by Nd:YAG laser therapy
  439. Apolipoprotein AI and alcoholic liver disease
  440. Multivariate analysis of prognostic factors in fulminant hepatitis B
  441. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives
  442. A randomized clinical trial of supplementary parenteral nutrition in jaundiced alcoholic cirrhotic patients
  443. The retrieval of randomized clinical trials in liver disease from the medical literature
  444. Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients
  445. Psoriasis, alcohol, and liver disease.
  446. Relationships between liver histologic lesions and portal hypertension in patients with alcoholic cirrhosis
  447. Propranolol for prevention of recurrent GI bleeding
  448. Adrenocorticosteroid administration and peptic ulcer: A critical analysis
  449. A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report
  450. HEPATITIS B VACCINE: A DIAGNOSTIC TEST FOR PREVIOUS HEPATITIS B VIRUS INFECTION?
  451. Prognostic Value of Total Serum Bilirubin/γ-Glutamyl Transpeptidase Ratio in Cirrhotic Patients
  452. Adrenocorticosteroid Therapy and Peptic-Ulcer Disease
  453. Efficiency of respiratory assistance in cirrhotic patients with liver failure
  454. Recurrent bleeding and propranolol?
  455. Relations Between Effectiveness of a Diagnostic Test, Prevalence of the Disease, and Percentages of Uninterpretable Results
  456. Secretory Diarrhea and Prostaglandin D2Overproduction in Systemic Mastocytosis
  457. Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: Assessment by the artificial pancreas
  458. Propranolol in Gastrointestinal Bleeding from Cirrhosis
  459. Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis
  460. Upper digestive tract hemorrhage in cirrhotic patients
  461. PECTIN EFFICACY IN INSULIN-TREATED DIABETICS ASSESSED BY THE ARTIFICIAL PANCREAS
  462. Hepatocellular Carcinoma in NAFLD
  463. Alcoholic Liver Disease
  464. Progression of Fibrosis